See other companies on Welcome to the Jungle
Parse Biosciences
Single-cell sequencing solutions for researchers
- 101-200 employees
- B2B
- Biology
- Science
- MedTech
- Interbay, Seattle, WA
Jump to section
Company mission
Parse Biosciences' mission is to accelerate progress in human health and scientific research.
Our take
Parse Biosciences provides researchers with a range of scalable solutions for single-cell sequencing. This is a methodology that’s rapidly increasing in popularity, having already led to significant discoveries in cancer treatment, immunity, stem cell therapy, and various other areas.
Where Parse sees itself as superior to an already competitive market is how its patent-based products allow scientists to examine cells at scale, tailored to their own experimental needs, with no other benchtop lab instruments required.
Co-founders Alex Rosenberg and Charles Roco have been generating excitement across the industry ever since they published their proof of concept for their sequencing techniques in 2018, just before launching the company.
Since then, Parse has been growing impressively, using multiple funding rounds to expand its headcount, product range, and global footprint. Its latest round will support the company's continued expansion as it scales to meet increasing demand and serves its long list of academic, biotech, and pharma customers.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Our offices include: State of the art fitness center, spectacular waterfront views, full locker rooms, secured day-use bike storage, café
- Parental leave
- 401(k)
- Generous time off policy
- Free snacks
- Equity in the company
- Medical, vision, and dental coverage for employees and dependents
Funding (last 2 of 4 rounds)
Dec 2023
$25m
SERIES C
Feb 2022
$41.5m
SERIES B
Total funding: $74.7m
Leadership
Alex Rosenberg
(CEO)Co-invented the single cell technology behind Parse’s foundational platform while a Commercialization Fellow at the University of Washington. Published multiple times in eminent journals such as Cell and Science.
Charles Roco
(CTO)Was at the University of Washington prior to Parse, receiving several fellowships from the NIH and Fred Hutch Cancer Research Center. Previously contributed to innovations in drug delivery and microscopy at the Wyss Institute at Harvard and the University of Pennsylvania.